ZYMED LABORATORIES INC. – Trademark Portfolio
Entity Type: 03
ZYMED LABORATORIES INC. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include HISTOSTAIN. The owner is based in SOUTH SAN FRANCISCO, CA.
561 ECCLES AVENUE
SOUTH SAN FRANCISCO, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
ZYMED LABORATORIES INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does ZYMED LABORATORIES INC. have?
ZYMED LABORATORIES INC. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 3 cancelled.
What trademark classes does ZYMED LABORATORIES INC. file in?
ZYMED LABORATORIES INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ZYMED LABORATORIES INC.'s most well-known trademarks?
ZYMED LABORATORIES INC.'s registered trademark portfolio includes well-known marks such as HISTOSTAIN. These are among 1 currently registered trademark in the portfolio.
What is ZYMED LABORATORIES INC.'s trademark registration success rate?
ZYMED LABORATORIES INC. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.